VNDA Stock Analysis: Vanda Pharmaceuticals | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 373m USD | 12M Return: 30.7% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 5.24M
Qual. Beats: 0
Rev. Trend: 13.4%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) is a U.S.-based, small-cap biopharmaceutical company headquartered in Washington, D.C., incorporated in 2002 and listed on NASDAQ since 2006. It focuses on developing and commercializing therapies for high unmet medical needs globally, operating within the biotechnology sub-industry of the healthcare sector.
The companys commercial portfolio spans neurology, psychiatry, and sleep disorders, including Fanapt (schizophrenia and bipolar I disorder), HETLIOZ (non-24-hour sleep-wake disorder and sleep disturbances), PONVORY (relapsing multiple sclerosis), and NEREUS (motion-induced vomiting). Beyond marketed products, Vanda has a diversified pipeline exploring expanded indications for existing assets, such as HETLIOZ for jet lag and insomnia, alongside earlier-stage candidates like Imsidolimab (an IL-36R antagonist for inflammatory skin conditions), VTR-297 (hematologic malignancies and oncology), and VQW-765 (a nicotinic receptor agonist for anxiety and psychiatric disorders).
The business model is typical of clinical-stage and commercial biopharma firms: revenue is generated from a limited set of approved specialty drugs, while a significant portion of resources is directed toward R&D to expand indications and advance pipeline candidates. Like many small-cap biotechs, Vandas valuation tends to reflect pipeline and regulatory milestones rather than stable, diversified revenue streams.
- Fanapt LAI formulation FDA approval expands schizophrenia market
- HETLIOZ patent litigation defends against generic competition
- Tradipitant GLP-1 side effect opportunity targets large adjacent market
| Net Income: -239.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.29 > 0.02 and ΔFCF/TA -20.28 > 1.0 |
| NWC/Revenue: 72.36% < 20% (prev 151.0%; Δ -78.61% < -1%) |
| CFO/TA -0.29 > 3% & CFO -126.5m > Net Income -239.5m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.16 > 1.5 & < 3 |
| Outstanding Shares: last quarter (59.5m) vs 12m ago 1.59% < -2% |
| Gross Margin: 92.46% > 18% (prev 93.47%; Δ -1.01% > 0.5%) |
| Asset Turnover: 40.88% > 50% (prev 31.86%; Δ 9.02% > 0%) |
| Interest Coverage Ratio: -100.0k > 6 (EBIT TTM -149.7m / Interest Expense TTM 1.0) |
| A: 0.36 (Total Current Assets 293.2m - Total Current Liabilities 135.6m) / Total Assets 433.5m |
| B: -1.02 (Retained Earnings -443.3m / Total Assets 433.5m) |
| C: -0.28 (EBIT TTM -149.7m / Avg Total Assets 532.7m) |
| D: 1.84 (Book Value of Equity 280.8m / Total Liabilities 152.8m) |
| Altman-Z'' = -0.91 = CCC |
| DSRI: 1.18 (Receivables 56.9m/44.6m, Revenue 217.8m/201.4m) |
| GMI: 1.01 (GM 93.47% / 92.46%) |
| AQI: 0.87 (AQ_t 0.29 / AQ_t-1 0.33) |
| SGI: 1.08 (Revenue 217.8m / 201.4m) |
| TATA: -0.26 (NI -239.5m - CFO -126.5m) / TA 433.5m) |
| Beneish M = -2.92 (Cap -4..+1) = A |
As of July 08, 2026, the stock is trading at USD 6.39 with a total of 771,991 shares traded. Over the past week, the price has changed by +4.07%, over one month by +7.58%, over three months by -14.23% and over the past year by +30.67%.
Current recommended Stop Loss: 6.10 (which is 4.5% or 1.2 ATR below the current price).
Vanda Pharmaceuticals has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy VNDA.
- StrongBuy: 1
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 14.1 | 121.1% |
P/E Forward = 86.9565
P/S = 1.7148
P/B = 1.3301
P/EG = 2.2319
Revenue TTM = 217.8m USD
EBIT TTM = -149.7m USD
EBITDA TTM = -136.2m USD
Long Term Debt = 7.05m USD (estimated: total debt 13.1m - short term 6.02m)
Short Term Debt = 6.02m USD (from shortTermDebt, last quarter)
Debt = 13.1m USD (from shortLongTermDebtTotal, last quarter) (leases 13.1m already included)
Net Debt = -189.2m USD (calculated: Debt 13.1m - CCE 202.3m)
Enterprise Value = 184.2m USD (373.4m + Debt 13.1m - CCE 202.3m)
Interest Coverage Ratio = -149.7m (Ebit TTM -149.7m / Interest Expense TTM 1.0)
EV/FCF = -1.45x (Enterprise Value 184.2m / FCF TTM -127.3m)
FCF Yield = -69.11% (FCF TTM -127.3m / Enterprise Value 184.2m)
FCF Margin = -58.45% (FCF TTM -127.3m / Revenue TTM 217.8m)
Net Margin = -110.0% (Net Income TTM -239.5m / Revenue TTM 217.8m)
Gross Margin = 92.46% ((Revenue TTM 217.8m - Cost of Revenue TTM 16.4m) / Revenue TTM)
Gross Margin QoQ = 90.05% (prev 93.30%)
Tobins Q-Ratio = 0.42 (Enterprise Value 184.2m / Total Assets 433.5m)
Interest Expense / Debt = 0.00% (Interest Expense 1.0 / Debt 13.1m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -118.3m (EBIT -149.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.16 (Total Current Assets 293.2m / Total Current Liabilities 135.6m)
Debt / Equity = 0.05 (Debt 13.1m / totalStockholderEquity, last quarter 280.8m)
Debt / EBITDA = 1.39 (negative EBITDA) (Net Debt -189.2m / EBITDA -136.2m)
Debt / FCF = 1.49 (negative FCF - burning cash) (Net Debt -189.2m / FCF TTM -127.3m)
Total Stockholder Equity = 390.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -44.97% (Net Income -239.5m / Total Assets 433.5m)
RoE = -61.41% (Net Income TTM -239.5m / Total Stockholder Equity 390.1m)
RoCE = -37.70% (EBIT -149.7m / Capital Employed (Equity 390.1m + L.T.Debt 7.05m))
RoIC = -40.35% (negative operating profit) (NOPAT -118.3m / Invested Capital 293.1m)
WACC = 6.66% (E(373.4m)/V(386.5m) * Re(6.89%) + D(13.1m)/V(386.5m) * Rd(0.00%) * (1-Tc(0.21)))
Discount Rate = 6.89% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.56 | Cagr: 1.48%
[DCF] Fair Price = unknown (Cash Flow -127.3m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.33 | # QB: 0
Revenue Correlation: 13.45 | Revenue CAGR: 1.24% | SUE: -0.07 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.59 | Chg30d=+3.05% | Revisions=-38% | Analysts=4
EPS next Quarter (2026-09-30): EPS=-0.51 | Chg30d=+3.15% | Revisions=+12% | Analysts=4
EPS current Year (2026-12-31): EPS=-2.27 | Chg30d=+2.01% | Revisions=+12% | GrowthEPS=+39.4% | GrowthRev=+21.2%
EPS next Year (2027-12-31): EPS=-0.77 | Chg30d=+12.50% | Revisions=-29% | GrowthEPS=+66.0% | GrowthRev=+36.1%
[Analyst] Revisions Ratio: -14% (up=8, down=11)